ProQR Therapeutics

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its financial and operating results for the third quarter ended September 30, 2021, and provided a business update.

ProQR Announces Third Quarter 2021 Operating and Financial Results

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the appointment of Theresa Heggie as Chief Commercial Officer reporting to Daniel de Boer, Founder and CEO. In this newly created leadership position, Ms. Heggie will be responsible for overseeing the Company's commercial strategy and global commercial operations. She joins as the Company prepares for the top-line results from its Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 in the first half of 2022.

ProQR Appoints Theresa Heggie as Chief Commercial Officer

Today, we revisit ProQR Therapeutics, an intriguing developmental concern for the first time since early this year.

Investment Case On ProQR Therapeutics Gets More Enticing

Investors need to pay close attention to ProQR (PRQR) stock based on the movements in the options market lately.

Implied Volatility Surging for ProQR (PRQR) Stock Options

A new collaboration deal with Eli Lilly could be worth up to $1.3 billion.

Here's Why ProQR Stock Surged on Thursday

The stock price of ProQR Therapeutics N.V. (Nasdaq: PRQR) increased over 13% pre-market this morning.

PRQR Stock: Why It Is Trading Higher Today

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that ProQR management will host an investor conference call and webcast to discuss the Company's Axiomer RNA editing technology platform following the recently announced partnership with Lilly. ProQR will host the call on September 9, 2021, at 8:15am EDT.

ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), today announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The companies will use ProQR's proprietary Axiomer® RNA editing platform to progress new drug targets toward clinical development and commercialization.

ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 06, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a virtual oral presentation of data from the Company's Phase 1/2 Stellar trial of QR-421a at the EURETINA virtual congress held September 9-12, 2021. It is the first time the Stellar trial data is presented at a medical congress. The paper will be made available on the EURETINA platform at the start of the congress.

ProQR Announces Virtual Presentation at EURETINA 2021

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will participate in the following upcoming investor conferences:

ProQR Announces Upcoming Investor Conferences

LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will present at the upcoming HC Wainwright Ophthalmology Virtual Conference. The presentation will be available on demand on August 17, 2021, at 7:00 am EDT.

ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its financial and operating results for the second quarter ended June 30, 2021, and provided a business update.

ProQR Announces Second Quarter 2021 Operating and Financial Results

PRQR is using antisense RNA technology to target inherited retinal diseases. They have strong data from one indication, and decent data from another.

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will present during a fireside chat at the upcoming JMP Securities Life Sciences Conference. The presentation will be webcast live on June 17, 2021, from 3:00 – 3:25pm EDT.

ProQR to Present at Upcoming JMP Securities Life Sciences Conference

ProQR (PRQR) delivered earnings and revenue surprises of -7.14% and -92.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) --   ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its financial and operating results for the first quarter ended March 31, 2021 and provided a business update.

ProQR Announces First Quarter 2021 Operating and Financial Results

Yarrow Biotechnology Inc, a newly created company by RTW Investments LP, has in-licensed exclusive rights to ProQR Therapeutics N.V.'s (NASDAQ: PRQR) antisense oligonucleotide technology to develop and commercialize potential therapies for an undisclosed non-ophthalmic target.

ProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development Pact

The stock price of ProQR Therapeutics N.V. (NASDAQ: PRQR) increased from $6.36 to $6.81 (up 7.08%) pre-market.

PRQR Stock: From $6.36 To $6.81 (7.08% Increase) Pre-Market Explanation

Costco

FedEx

Alphabet

DISH Network

PG&E

Clorox

With the trading day more than halfway over, the broad markets were somewhat mixed on the day.

Alphabet, Costco, FedEx, UPS and More Monday Afternoon Analyst Calls

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual oral presentation of data from the Company's Phase 1/2 InSight extension trial of sepofarsen and live Q&A session at the Association for Research in Vision and Ophthalmology (ARVO) held May 1-7, 2021. This is an encore presentation of the InSight study data that was presented during the Expert Perspectives Call in July 2020 . We expect to present new data from the InSight study in H2 2021.

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will host 1x1 meetings through the Kempen Life Sciences Conference 2021 Thematic Virtual Series on April 28, 2021.

ProQR Announces Participation in Upcoming Kempen Life Sciences Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the publication in the scientific journal Nature Medicine titled “Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: a case report” describing durable vision improvement after treatment with sepofarsen in a clinical trial for CEP290 mediated Leber congenital amaurosis 10 (LCA10).

ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10

A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month.

An End to This Rare Syndrome Could Be an Opportunity for Investors

LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the closing of its previously announced underwritten public offering of 13,846,154 ordinary shares at a price to the public of $6.50 per share. All of the shares were offered by ProQR. The closing included the full exercise of the underwriters' option to purchase up to 2,076,923 additional ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds from the offering totaled approximately $103.5 million, before deducting underwriting discounts and commissions and offering expenses.

ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters' Option to Purchase Additional Shares

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation at the Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) held April 9-11, 2021.

News for ProQR Therapeutics Stock (PRQR)